Kimal Arici M, Topalkara A, Güler C
Department of Ophthalmology, Cumhuriyet University, School of Medicine, Sivas, Turkey.
Int Ophthalmol. 1998;22(1):37-42. doi: 10.1023/a:1006176713983.
To evaluate the additive ocular hypotensive effect of latanoprost and dorzolamide in combination, on intraocular pressure reduction in patients with elevated intraocular pressure (IOP).
Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were randomly assigned to two parallel treatment groups. The treatment period was twenty days. Fifteen patients (Group 1) received latanoprost once daily during the first ten days and, in addition, dorzolamide three times daily during the second ten days. Fifteen patients (Group 2) received dorzolamide three times daily during the first ten days and, in addition latanoprost, once daily during the second ten days. IOP was measured and conjunctival hyperemia was evaluated.
In Group 1, the mean IOP on day 0 was 26.8 mm Hg; on day 10, 18.7 mm Hg; and on day 20, 15.9 mm Hg. In Group 2, the mean IOP on day 0 was 26.3 mm Hg; on day 10, 21.2 mm Hg; and on day 20, 16.1 mm Hg. Both groups had clinically significant IOP-lowering effect on day 10 as compared with baseline day (30.2% and 19.4% respectively) (p<0.01). When dorzolamide was added to latanoprost, the additional IOP reduction was 2.8 mm Hg (15%) (p<0.01) compared with 5.1 mm Hg (24.1%) (p<0.01) when latanoprost was added to dorzolamide. No local serious adverse reactions were observed. A mild but statistically significant increase in conjunctival hyperemia was seen in latanoprost applied patients.
The results showed that latanoprost and dorzolamide can be combined successfully to reduce IOP with their additive effects.
评估拉坦前列素和多佐胺联合使用对眼压升高患者降低眼压的附加降压效果。
30例患有高眼压症或早期囊膜性或原发性开角型青光眼且眼压升高的患者被随机分为两个平行治疗组。治疗期为20天。15例患者（第1组）在前10天每天接受一次拉坦前列素治疗，此外，在后10天每天接受三次多佐胺治疗。15例患者（第2组）在前10天每天接受三次多佐胺治疗，此外，在后10天每天接受一次拉坦前列素治疗。测量眼压并评估结膜充血情况。
第1组中，第0天的平均眼压为26.8 mmHg；第10天为18.7 mmHg；第20天为15.9 mmHg。第2组中，第0天的平均眼压为26.3 mmHg；第10天为21.2 mmHg；第20天为16.1 mmHg。与基线日相比，两组在第10天均有临床上显著的眼压降低效果（分别为30.2%和19.4%）（p<0.01）。当多佐胺添加到拉坦前列素中时，与拉坦前列素添加到多佐胺中时相比，额外的眼压降低为2.8 mmHg（15%）（p<0.01），而拉坦前列素添加到多佐胺中时额外眼压降低为5.1 mmHg（24.1%）（p<0.01）。未观察到局部严重不良反应。在使用拉坦前列素的患者中观察到结膜充血有轻度但具有统计学意义的增加。
结果表明，拉坦前列素和多佐胺可以成功联合使用，通过它们的相加作用降低眼压。
